Loading…
Partnership aims to expand Co-Diagnostics' presence in the Middle East.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the signing of a strategic Memorandum of Understanding (MOU) with a partner in the Kingdom of Saudi Arabia. The agreement is intended to introduce Co-Diagnostics' Co-Dx™ PCR platform to the Middle East market.
The MOU outlines the terms of collaboration between Co-Diagnostics and its Saudi partner, focusing on the distribution and implementation of the Co-Dx™ PCR technology within the region. This partnership is expected to enhance Co-Diagnostics' market reach and strengthen its global footprint.
As of the latest available data, Co-Diagnostics has a free float of 54,058,000 shares and 60,893,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.